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Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis. It typically 
affects the lungs (pulmonary TB) but can affect other sites as well – extra-pulmonary TB. 
The disease is air born: germs are transmitted by inhalation of droplets containing the 
bacilli. The germs are expelled into the air by people who are sick with pulmonary TB, 
by coughing or sneezing 1. Once people are infected, disease may ensue in some 10% 
of those infected 2. Estimates for the risk of TB after infection have varied among studies 
between 7.3% / 100 life years 3, 2.5% in the first 5 years after infection 4 but also much 
higher risks (>11.5%) have been reported 5. The extremes of age – young children and the 
elderly and also, the immuno-compromised, have a considerably higher risk to develop 
active TB 3,5. 
 Mortality rates of TB are high if no specific treatment is given; in studies of the natural 
history of the disease among sputum smear-positive and HIV-negative cases of pulmonary 
TB, around 70% died within 10 years; among culture-positive (but smear-negative) cases, 
20% died within 10 years 6.
Currently there is no effective vaccine to prevent TB in adults, and although it provides 
some protection to infants and children 7,8, the TB epidemic has largely been unaffected 
by the current BCG vaccination programs.
 Effective drug treatment was first developed in the 1940s. In 1943, the first drug that 
was discovered to be effective against TB was streptomycin. Albert Schatz made this 
discovery while working at the laboratory of Selman Waksman at Rutgers University in 
New Jersey 9. Other drugs for TB, like Jörgen Lehmann’s discovery of para-aminosalicylic 
acid (PAS) followed shortly thereafter 10. The most effective first-line anti-TB drug, 
rifampicin, belongs to a group of compounds that are the natural product of Nocardia 
mediterranei. Rifampicin became available for clinical use in 1968 – 11 years after the first 
rifamycin derivative was isolated 11. The currently recommended treatment for new cases 
of drug-susceptible TB is a six-month regimen of four first-line drugs: isoniazid, rifampicin, 
ethambutol and pyrazinamide 1.  Further reduction of treatment duration for drug-
susceptible TB was tested in recent years by adding moxifloxacin, a recent generation 
fluoroquinolone, to standard treatment. The hypothesis was that by adding this potent 
compound to standard treatment, success rates with a four-month regimen would be 
non-inferior to standard care. Unfortunately, successful outcome – being 96% in the 
standard 6-month regimen with first-line drugs – declined to 87%, thereby rejecting the 
hypothesis that with addition of this potent TB drug, standard treatment duration could 
be shortened to 4 months only 12. This disappointing result suggests that for the slowly 
replicating persister phenotype M. tuberculosis, later generation fluoroquinolones may 
not have an added benefit in combination with rifampicin. Indeed rifampicin remains the 
most effective drug currently available to eradicate these organisms, thereby providing 








 Drug resistant TB (DR-TB) was identified soon after the introduction of TB treatment. 
The first trial with streptomycin was conducted in 1947. It showed that streptomycin was 
effective against pulmonary TB, but there was also evidence of some toxicity. Patients in 
the streptomycin group showed an initial improvement, often however followed by their 
subsequent deterioration when their bacilli became drug resistant 14,15.  Soon it was notice 
that combined therapy of streptomycin and PAS and isoniazid prevented the emergence 
of resistance 16.
Although its causes are genetic and microbial, DR-TB is essentially a man-made 
phenomenon. From a microbiological perspective, resistance is caused by a genetic 
mutation that results in a drug being ineffective against the mutant bacilli. From a clinical 
and programmatic perspective, it is an inadequate or poorly administered treatment 
regimen that allows a drug-resistant strain to become the dominant strain in a patient 
infected with TB. 
There are two principal pathways leading to the development of DR-TB 1:
(1) Acquired (secondary) drug resistance:
  Acquired drug resistance is the result of inadequate, incomplete or poor treatment 
quality that allows the selection of mutant resistant strains in the lesions of an 
individual suffering from TB. If drug-susceptible TB is treated with a regimen 
exclusively based on a single effective TB drug, there is a high risk that bacteria with 
drug-resistant mutations will be selected and multiply further during the course of 
treatment, eventually becoming the dominant strain. If a person infected with a strain, 
initially resistant to a specific drug is treated with that medicine plus one additional 
medicine, then there is a risk of developing resistance to that additional medicine. 
Step-wise additions of single drugs may eventually lead to more severe patterns of 
drug resistance and eventually to untreatable forms of TB. 
(2) Primary drug resistance: 
  If a patient with drug-resistant TB is the source of infection, the secondarily infected 
individual acquires primary resistant TB.   
Simultaneous natural mutations in the M. tuberculosis genome resulting in resistance 
to more than one TB medicine are exceedingly rare: in wild-type M. tuberculosis strains, 
typically 2.25x1010 cell divisions result in rifampin resistance, and 2.5x108 in isoniazid 
resistance. Still, because of the huge numbers of bacilli present in lesions of TB patients 
(1010 – 1012) antimicrobial pressure by only one active drug may quickly result in facilitating 
growth of drug resistant mutants 17. 




With subsequent monotherapy, mono-resistance may ultimately result in multi-drug 
resistance. Therefore, appropriate treatment with a combination of several quality-
assured TB medicines dramatically diminishes the risk of selection of resistant strains. This 
is the rationale for using a combination of quality-assured medicines when treating TB, 
while ensuring good adherence.
 Definitions of DR-TB 2
•	 MDR-TB: Multidrug resistance: resistance to at least both isoniazid and rifampicin 
(the two most powerful anti-TB drugs). 
•	 XDR-TB: Extensive drug resistance: resistance to any fluoroquinolone and to at least 
one of three second-line injectable drugs (capreomycin, kanamycin and amikacin), 
in addition to multidrug resistance. 
Treatment for MDR-TB needs to be longer than the so-called short course (6 months) that 
has been shown to be highly effective for drug-susceptible TB; indeed it requires more 
expensive and more toxic drugs. For most patients with MDR-TB, the duration of treatment 
regimens recommended by the WHO until 2016 were 20 months, with treatment success 
rates still being much lower than for drug-susceptible TB. In 2016 the WHO endorsed new 
guidelines allowing duration of treatment could be reduced to 9-12 months for selected 
cases 3.  Patients who have been previously treated with 2nd line drugs; those in whom 
resistance to fluoroquinolones and 2nd line injectable agents has been demonstrated 
or is considered highly likely should still receive 20 months of treatment. Although 
treatment for the subset of patients with relatively uncomplicated MDR-TB is shortened 
by 8-9 months, treatment still lasts long; this is due to the fact that very few 2nd line drugs 
have the sterilizing effect to replace rifampicin. Clofazimine is one of the few drugs with 
the potential to eradicate persister organisms 18.  Interestingly, relatively short-course 
treatment regimens with promising success rates have typically included this compound 
19,20. 
The global TB problem 4
In 2012, worldwide over 8 million people developed TB and approximately 1.3 million 
people died from the consequences of TB in 2013 21. The incidence of TB is especially high in 
resource-limited countries. Due to immigration of migrants from high prevalence countries, 
TB is not only a low-income country problem, but affects countries worldwide 22.
2  WHO 2013. Definitions and reporting framework for tuberculosis. TB/2013.2). WHO/HTM/.www.who.int/
iris/bitstream/10665/79199/1/9789241505345_eng.pdf
3  WHO. WHO treatment guidelines for drug-resistant tuberculosis. 2016 update. http://www.who.int/tb/
areas-of-work/drug-resistant-tb/MDRTBguidelines2016.pdf?ua=1
4  WHO. Global tuberculosis report 2014. http://www.who.int/tb/publications/global_report/en/ ISBN 978 









 Of the estimated 9 million people who developed TB in 2013, more than half (56%) 
were in the South-East Asia and Western Pacific Regions. A further one quarter were 
in the African Region, which also had the highest rates of cases and deaths relative to 
population. India and China alone accounted for 24% and 11% of total cases, respectively.
An estimated 1.1 million (13%) of the 9 million people who developed TB in 2013 were HIV-
positive. The number of people dying from HIV-associated TB has been falling for almost 
a decade. The African Region accounts for about four out of every five HIV-co-infected TB 
patients and TB deaths among people who were HIV-co-infected. 
 In 2011, an estimated 310,000 of all newly reported TB cases had MDR-TB 1 and currently, 
3.5% (95% CI: 2.2–4.7%) of new TB cases and 20.5% (95%CI: 13.6–27.5%) of previously 
treated cases are estimated to have MDR-TB. This translates into an estimated 480.000 
people having developed MDR-TB in 2013. On average, an estimated 9.0% of patients with 
MDR-TB have XDR-TB. MDR-TB continues to threaten the progress made in TB control. The 
emergence of XDR-TB has heightened this threat. XDR-TB has been identified in all regions 
of the world since 2006 23, and was announced by the World Health Organization (WHO) 
as a serious emerging threat to global public health, especially in countries with a high 
prevalence of HIV infection. In many areas such as Africa, the extent of drug resistance 
is unknown and in most resource-constrained countries the treatment of patients with 
MDR-TB is absent or inadequate. Indeed, despite efforts made to fight TB and HIV co-
infection, TB incidence that had declined in the last decade seems to have plateaued in 
recent years 24 – and this may be explained by the emergence of TB drug resistance. 
TB in the Netherlands
In the Netherlands with currently 17 million inhabitants, TB incidence started to decline 
long before modern TB drug treatment was introduced, while after the introduction of 
modern drug treatment, TB incidence has continued to decline. Over the last decade 
the number of TB patients in the Netherlands declined with 38%. Since 2013, the annual 
incidence has plateaued at around 850, which is an incidence of 5.1 per 100,000 population 
(NTR 5). 
 In 2014, the Netherlands endorsed the World Health Organization’s Global End TB 
Strategy, which includes the objective to reduce TB incidence with 90 % by 2035. The 
National Tuberculosis Control Plan 2016-2020 sets out the interventions that are needed 
to achieve the interim-objectives of reducing TB transmission and case numbers in the 
Netherlands with 25% over the next 5 years. The main new intervention to reach these 
targets is to screen new immigrants and asylum-seekers for latent TB infections and 
providing preventive treatment to those infected 25.
5  NTR: Nederlands Tuberculose Register (Netherlands Tuberculosis Register). 
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 Today, the majority of TB patients in the Netherlands are foreign born (74%). The 
percentage TB patients tested for HIV increased from 28% in 2008 to 51% in 2013. The 
percentage of HIV-infected TB patients declined over the last decade to 2.0% in 2013 
(3.9% of patients with a known HIV-status). In the last five years the number of patients 
with MDR-TB in the Netherlands varied between 10 and 20, 1-2% of the total number of TB 
patients. In 2013, 17 patients with MDR-TB were registered - all were foreign born. 
 Although these numbers seem trivial compared to the global figures, the open 
borders and subsequent in-bound travel from all over the world call for vigilance. This is 
particularly true for MDR- and XDR-TB. 
 All TB cases in the Netherlands are treated according to national TB guidelines and 
notified to municipal health authorities with their public health TB teams that treat 
uncomplicated cases, and initiate contact investigation and screening activities. With 
declining TB rates, training was maintained while TB departments merged. The NTR was 
constructed and maintained by KNCV until 2012, since when register is managed at the 
department of Epidemiology and Surveillance of the National Institute of Public Health 
and the Environment in the Netherlands. Two dedicated and well-equipped TB Centres – 
the TB Centre in Beatrixoord, Haren, part of the University Medical Centre Groningen, and 
the TB Unit in Dekkerswald, part of the Radboud University Medical Centre in Nijmegen 
- provide care for patients with co-morbid and complicated TB, including all cases with 
MDR-TB. 
Outline of the thesis
In Chapter 2, we explore host-pathogen interactions, the current concepts of local and 
systemic immune responses to M tuberculosis with a focus on potentially modifiable 
factors (like iron and vitamin D), the BCG and newer TB vaccines; and an update is given 
on monitoring of disease activity.  We will address the importance of differentiating 
between real disease activity (treatment failure) and a paradoxical response, defined as 
clinical worsening with increasing inflammation but with decreasing mycobacterial load. 
The paradoxical response in HIV+ patients is called: Immune Reconstitution Inflammatory 
Syndrome (IRIS). This differentiation between treatment failure and paradoxical reaction / 
IRIS is particularly important in HIV-patients with MDR-TB. The crucial question clinicians 
face is whether to change their (second-line) TB-medication or continue and even consider 
addition of immunosuppressive drugs, like corticosteroids.  Host-pathogen reactions 
are based on the interplay between the pathogen and its usual host, thereby providing 
genetic selection pressure with impact on both M. tuberculosis and its human host. The 








 In Chapter 3, we address treatment outcome of MDR-TB in the Netherlands. The first 
study describes the results of the period from 1985 until 1th September 1998 and the 
second study describes the results of a 10-year period of 2000-2009. The case mix of MDR-
TB patients is discussed with emphasis on physical and psychiatric co-morbidities and 
language and cultural barriers – and we briefly discuss the financial impact of MDR-TB 
treatment.
 We discuss different factors predicting successful outcome: drug combination; drug 
sensitivity testing (DST) performed in a central reference laboratory; drug treatment 
being adjusted to DST and pharmacokinetic (PK) measurements; team commitment; 
collaboration in a national TB program; and financial input.  We hypothesize that all of 
these factors – with emphasis on PK/PD modeling – predict treatment outcome.
 
Chapter 4 is dedicated to the aminoglycosides amikacin and kanamycin (‘the injectables’). 
The aminoglycosides amikacin and kanamycin are considered important and effective 
drugs used in the treatment of MDR-TB. However they are also notorious for their side 
effects: nephrotoxicity and in particular ototoxicity. Therefore one of the major challenges 
with the injectables is to diminish their intrinsic toxicity that is drug concentration 
dependent - while maintaining efficacy. 
 Using a retrospective survey strategy of patients with culture-confirmed MDR-TB 
or XDR-TB and who met the inclusion criteria, we evaluate the PK parameters of the 
aminoglycosides amikacin and kanamycin to detect predictors for PK parameters, efficacy 
and toxicity. In our study we evaluate PK/PD equations as a proxy for efficacy, as well as 
toxicity - notably, ototoxicity or nephrotoxicity at a lower dose (median dose of 6.5 mg/
kg) than recommended in the World Health Organization (WHO) guidelines (15 mg/kg/
day, with a maximum of 1000 mg daily).
 To balance between efficacy and toxicity, we explore a population pharmacokinetic 
model to help optimize drug exposure.  We hypothesize that with individualized 
treatment, using PK/PD modeling, toxicity can be reduced while maintaining efficacy.
In Chapter 5 we focus on ertapenem, one of the carbapenems, labeled for other bacterial 
infections. Ertapenem is a drug that was not listed in the group 5 WHO drugs with 
unknown efficacy and has also not been included in the updated 2016 recommendations. 
We explore the potential use of this compound in the treatment of MDR-TB (including 
XDR-TB).  
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